Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

What Was Tested

In this phase 2 trial, researchers set out to test Retatrutide.

It had seven arms (groups): one (experimental), one (experimental), one (experimental), one (experimental) and one (experimental).

The registry classes the interventions as behavioral and drug.

Who Took Part

The registry lists 300 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 18 to 75 years (inclusive) at time of informed consent. Motivated and able/willing to self-inject (or have trained assistance if needed) and follow study procedures, including lifestyle advice and questionnaires. Male and/or female; contraception requirements apply; women of childbearing potential must have negative pregnancy tests at specified visits and should not be breastfeeding. Capable of giving signed informed consent and complying with protocol requirements.

The full record lists 6 inclusion and 36 exclusion criteria; among the exclusions: history of diabetes mellitus (type 1 or type 2), ketoacidosis, or hyperosmolar state/coma; self-reported change in body weight \>5 kg within 3 months prior to screening; prior or planned surgical treatment for obesity (exceptions: liposuction/abdominoplasty \>1 year prior).

How the Study Was Run

The set-up was randomized, parallel-group and single-blind.

Random assignment meant chance, not the researchers, decided who got Retatrutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Only one side, usually the participants, was kept unaware of whether Retatrutide was given.

Those kept unaware of assignments: participant.

It started in 2026-02-15 with completion listed for 2027-03-14.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Mean percent change in body weight from randomization/baseline to Week 24 (time frame: 24 weeks).

It also tracked 6 secondary outcomes, for example Mean percent change in body weight from baseline to Week 48, Mean change in body weight (kg) at Weeks 24 and 48, Mean change in BMI (kg/m²) at Weeks 24 and 48, Mean change in waist circumference (cm) at Weeks 24 and 48 and Safety and tolerability outcomes (e.g., treatment-emergent adverse events; serious adverse events; discontinuations due to adverse events).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Retatrutide in 300 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Retatrutide compound page, all human trials.